



Plenary sitting

B8-0007/2017

3.1.2017

MOTION FOR A RESOLUTION

pursuant to Rule 133 of the Rules of Procedure

on multiple sclerosis treatment

Mireille D'Ornano

Motion for a European Parliament resolution on multiple sclerosis treatment

The European Parliament,

- having regard to Article 168 of the Treaty on the Functioning of the European Union,
- having regard to Rule 133 of its Rules of Procedure,
- A. whereas multiple sclerosis is an auto-immune disease which affects an average of 30 people per 100 000 worldwide (World Health Organisation, 2008), but which is particularly prevalent in Europe (80 cases per 100 000 people);
- B. whereas multiple sclerosis treatments help to mitigate the worst phases of the disease but can have serious side-effects;
- C. whereas, according to the New England Journal of Medicine (21 December 2016), one study that is currently in phase III of clinical trials and which is being carried out by the pharmaceutical companies Biogen and Genetech in collaboration with Basel University Hospital has found an antibody that slows the progression of multiple sclerosis;
- D. whereas human trials are also underway at the Hospital Clinic and the Hospital Germans Trias i Pujol (Barcelona) for a dendritic cell therapy against multiple sclerosis;
- 1. Calls on the Commission to support these two European research programmes and all other research programmes being carried out for the purpose of finding a treatment for multiple sclerosis.